ctDNA monitoring to optimize immunotherapy treatment decisions
Dive into the latest data highlighting ctDNA for immunotherapy treatment response monitoring
Watch Video
Resource Library
Natera Resource Hub - your source for articles and videos.
-
-
How Dr. Daniel Brennan uses diverse approaches to dd-cfDNA surveillance - immunosuppression modulation and tracking total dd-cfDNA over time
In this episode of our Inside the ProActive Study Podcast, Dr. Daniel Brennan gives us his thoughts on: • Why “50% of DSA’s are clinically meaningless” when monitoring for rejection. • His dd-cfDN
Listen Now
-
How Dr. Millie Samaniego bridged the gap between study use and routine care by extending protocolized use
In this episode of our Inside the ProActive Study Podcast, Dr. Millie Samaniego-Picota tells us about: • Her experience expanding the ProActive Study Protocol schedule to all her patients • How her
Listen Now
-
How Dr. Daniel Brennan uses diverse approaches to dd-cfDNA surveillance - immunosuppression modulation and tracking total dd-cfDNA over time
In this episode of our Inside the ProActive Study Podcast, Dr. Daniel Brennan gives us his thoughts on: • Why “50% of DSA’s are clinically meaningless” when monitoring for rejection. • His dd-cfDNA su
Watch Video
-
Have a question or comment?
Contact Us -
Circulating tumor DNA (ctDNA) dynamics and survival outcomes in patients with advanced NSCLC and high (≥50%) PD-L1 expression
Read More
-
Signatera NSCLC Data Sheet
Read More
-
How Dr. Millie Samaniego bridged the gap between study use and routine care by extending protocolized use
In this episode of our Inside the ProActive Study Podcast, Dr. Millie Samaniego-Picota tells us about: • Her experience expanding the ProActive Study Protocol schedule to all her patients • How her
Watch Video
-
How Dr. Yasir Qazi embraced cell-free DNA surveillance, an unaffected approach due to the recent CMS update
Hear from our ProActive Study Investigator In this episode of our Inside the ProActive Study Podcast, Dr. Yasir Qazi talks to us about: • His dd-cfDNA “surveillance journey” and protocol development.
Watch Video
-
How Dr. Matthew Cooper leverages dd-cfDNA to replace protocol biopsies for surveillance, in-line with ASTS recommended use
Listen Now
-
How Dr. Matthew Cooper leverages dd-cfDNA to replace protocol biopsies for surveillance, in-line with ASTS recommended use
In this episode of our Inside the ProActive Study Podcast, Dr. Matthew Cooper shares his insights on: • Utilizing cfDNA alongside DSA and biopsies before implementing his dd-cfDNA surveillance protoc
Watch Video
-
Detect. Monitor. Optimize: Signatera’s Impact on Breast Cancer Management
Learn more about the latest Signatera™ data in high-risk breast cancer: Newly published data from the I-SPY 2 trial reinforcing the utility of ctDNA monitoring
Watch Video
-
Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancer
Read More
-
Reproductive Carrier Screening Results With Maternal Health Implications During Pregnancy.
Souter, V., Prigmore, B., Becraft, E., et al. Obstetrics and Gynecology 2023 Aug 10
Read Publication
-
HIPAA Authorization to Release Records to a Partner/Significant-other
Read More
-
How Dr. Yasir Qazi embraced cell-free DNA surveillance, an unaffected approach due to the recent CMS update
Hear from our ProActive Study Investigator In this episode of our Inside the ProActive Study Podcast, Dr. Yasir Qazi talks to us about his dd-cfDNA “surveillance journey” and protocol development.
Listen Now
-
OH Patient Portal - Patient Slim Jim
Read More
-
Post-ASCO Summary: ctDNA as a patient selection and early efficacy marker in drug development
Our expert speakers will discuss the latest data from ASCO 2023 and other recent publications and congresses. This will be followed by a panel discussion on the future directions and implications for
Watch Video
-
22q11.2 deletion syndrome
Why to screen for 22q11.2 deletion syndrome during your pregnancy with NIPT.
Watch Video
-
Low fetal fraction results for clinicians
A guide to discussing a result with low fetal fraction from Panorama NIPT with patients.
Watch Video
-
Microdeletion syndromes
Why it’s important to screen for microdeletion syndromes during your pregnancy with NIPT.
Watch Video
-
Loading More...
